Jennison's Strategic Growth.
Jennison Associates Expands Major Stakes in UnitedHealth, Eli Lilly, and Key Energy Stocks.
Key Points
Jennison raised its UnitedHealth Group stake by 148,732 shares in Q2, bringing the total to 806,788 shares — a 22.6% quarter-over-quarter increase with the stake valued at about $335.3 million.
Jennison’s Eli Lilly stake reached 5,461,416 shares after adding 400,538 in the quarter; Lilly now accounts for roughly 3.9% of Jennison’s holdings and is the fund’s sixth-largest position, valued at about $6.55 billion.
Energy Transfer (ET) position climbed to 1,802,685 shares after purchasing 218,646 shares; the stake represents about 0.05% of the stock and is worth roughly $34.47 million.
Stryker (SYK) saw Jennison purchase 323,435 shares in the quarter, a stake valued at about $101.83 million and representing roughly 0.08% ownership.
Kinetik Holdings (KNTK) metrics highlighted in the period show a double-digit P/E of 19.32, a 12-month price range from $31.33 to $54.12, and about 21.11% of the stock owned by institutional investors, with the stock opening around $53.32.
Jennison Associates LLC made a broad push into major U.S. equities, expanding stakes in UnitedHealth Group, Eli Lilly, Energy Transfer, Stryker, and Kinetik Holdings. The moves signal a wide-ranging strategy across healthcare, energy, and medical technology sectors, according to Ticker Report.
The firm's largest position by value remains Eli Lilly, now worth roughly $6.55 billion after Jennison added 400,538 shares. That single stake alone represents about 3.9% of the fund's total holdings.
Jennison Bets Big on Eli Lilly and UnitedHealth
Eli Lilly is now Jennison's sixth-largest position after the firm boosted its stake to 5,461,416 shares, per Ticker Report. The $6.55 billion valuation makes it the standout holding in this round of buying. The 400,538 shares added in the quarter represent a significant vote of confidence in the drugmaker.
UnitedHealth Group also saw major activity. Jennison added 148,732 shares, lifting its total to 806,788 — a 22.6% jump quarter-over-quarter. The stake is now worth about $335.3 million, according to Ticker Report.
Energy and Medical Devices Round Out the Strategy
Jennison bought 218,646 shares of Energy Transfer, bringing its total to 1,802,685 shares. The position is worth roughly $34.47 million and represents about 0.05% of the company's total stock, according to Ticker Report.
In medical technology, Jennison picked up 323,435 shares of Stryker. That stake is now valued at about $101.83 million, equal to roughly 0.08% ownership of the company. Other institutions also added Stryker shares during the period, with River Wealth Advisors lifting its own stake by 7.5% to 29,350 shares, per Ticker Report.
Kinetik Holdings Draws New Institutional Money
Jennison also established a new position in Kinetik Holdings, joining other institutions moving into the stock. About 21.11% of Kinetik's shares are now owned by institutional investors, according to Ticker Report.
Kinetik's metrics look solid on paper. The stock carries a price-to-earnings ratio of 19.32, a figure that shows investors are paying a reasonable price relative to earnings. Its 12-month trading range runs from $31.33 to $54.12, and shares opened recently around $53.32 — near the top of that range.
Wider Institutional Buying Backs These Moves
Jennison is not alone in these bets. Multiple other institutional investors added to positions in UnitedHealth, Lilly, and Stryker during the same period, per Ticker Report. The overlap suggests broad market conviction rather than a contrarian play by a single fund.
Stryker also saw insider trading activity from company executives during the period, adding another data point for investors watching the stock. Taken together, the buying across five names — spanning drugs, insurance, pipelines, and medical devices — points to a diversified, high-conviction strategy from Jennison heading into the second half of 2026.
Sentiment
Mostly PositivePublishers
10
Articles
3
Reach
13
